AstraZeneca may have exited the COVID-19 vaccine market, but it is still hoping to protect vulnerable patients with its antibody sipavibart for pre-exposure prophylaxis (PrEP). The drugmaker said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback